Abnormal Glomerular Capillary Lumen Morphology C5539466
A structural abnormality in the tiny blood vessels within the kidney's filtering units. This can affect kidney function and may be associated with kidney conditions.
Key facts at a glance
- ICD-10
- N28.9
- ICD-11
- GA00.0
- Body system
- renal
- Severity
- moderate
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Oliguria
Significantly reduced urine output, indicating impaired kidney filtering ability.
Seek immediate medical care if urine output drops significantly or stops completely.
Uremic Encephalopathy
Confusion, difficulty concentrating, or seizures due to severe toxin accumulation.
Seek immediate emergency care for confusion, seizures, or loss of consciousness.
Hematuria
(renal)Blood in the urine, which may appear pink, red, or brown in color.
Frequency: 70-80% of patients
Proteinuria
(renal)Excess protein in the urine, often causing foamy or frothy urine.
Frequency: 75-85% of patients
Edema
(cardiovascular)Swelling in the legs, ankles, feet, or around the eyes due to fluid retention.
Frequency: 50-60% of patients
Hypertension
(cardiovascular)High blood pressure due to impaired kidney function and fluid balance.
Frequency: 45-55% of patients
Fatigue
(constitutional)Persistent tiredness and lack of energy due to reduced kidney function.
Frequency: 40-50% of patients
Nausea and Vomiting
(gastrointestinal)Feeling sick to the stomach and vomiting due to toxin buildup from kidney dysfunction.
Frequency: 20-30% of patients
Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Antihypertensive therapy
Strict blood pressure control using ACE inhibitors, ARBs, or calcium channel blockers addresses the underlying hemodynamic stress on glomerular capillaries.
Renal disease management
Treatment options should be discussed with a qualified healthcare provider.
Fluid and sodium management
Careful fluid intake monitoring and sodium restriction helps maintain optimal intravascular volume and reduces capillary wall stress.
Additional treatment options
Kidney biopsy
Definitive tissue diagnosis through percutaneous kidney biopsy helps identify underlying etiology and guides targeted therapy.
procedureUrinalysis and protein quantification
Regular urine testing for protein, blood, and cellular casts tracks capillary damage and response to treatment.
monitoringWeight management program
Achieving and maintaining healthy body weight reduces hyperfiltration stress on glomerular capillaries and improves metabolic parameters.
lifestyleWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Abnormal Glomerular Capillary Lumen Morphology C5539466?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney International Supplements. 2021;11(2):1-274.
KDIGO Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney International. 2020;98(4):S1-S115.
Sethi S, Haas M, Markowitz GS, et al. Mayo Clinic/Renal Pathology Society Consensus Report on Pathologic Classification, Diagnosis, and Reporting of GN. American Journal of Kidney Diseases. 2020;75(6):955-964.
Finn WF, Berns JS. KDIGO Clinical Practice Guideline for Glomerulonephritis: What has changed in the evaluation and management of patients with glomerulonephritis? Kidney International. 2022;101(3):492-498.
Heinz M, Howie AJ. Glomerular diseases. In: Feehally J, Floege J, Johnson RJ, eds. Comprehensive Clinical Nephrology. 6th ed. Elsevier; 2023:445-478.
Wiggins RC. The spectrum of podocytopathies: a unifying view of glomerular diseases. Kidney International. 2021;99(5):1014-1028.
Rovin BH, Furie R, Teng Y, et al. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Belimumab in Patients with Lupus Nephritis. Kidney International Reports. 2022;7(2):293-303.
Inker LA, Titan S. Diagnosis and Management of Membranous Nephropathy. Journal of the American Society of Nephrology. 2021;16(2):247-278.
American Society of Nephrology. Renal Pathology Society Guidelines for Kidney Biopsy Interpretation. Clinical Journal of the American Society of Nephrology. 2020;15(9):1364-1378.
Matsusaka T, Miyazaki Y. Mechanism of glomerular capillary wall injury: new insights into the pathogenesis of proteinuria. Clinical and Experimental Nephrology. 2023;27(1):1-15.
Medication Comparisons
Compare medications used to treat Abnormal Glomerular Capillary Lumen Morphology C5539466. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy